{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:26:06Z","timestamp":1788305166210,"version":"build-2803163510"},"reference-count":45,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,6,5]],"date-time":"2016-06-05T00:00:00Z","timestamp":1465084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Janssen Global Services, LLC"},{"name":"Millennium Pharmaceuticals, Inc."}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:p>This descriptive, cross\u2010sectional analysis evaluated the impact of baseline characteristics on health\u2010related quality of life (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\u2010QoL) at different stages of multiple myeloma (<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>). The bortezomib clinical\u2010trial programme evaluated <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\u2010QoL early and consistently, producing a large multi\u2010study dataset. Baseline data, captured using the European Organization for Research and Treatment of Cancer (<jats:styled-content style=\"fixed-case\">EORTC<\/jats:styled-content>) quality\u2010of\u2010life questionnaire (<jats:styled-content style=\"fixed-case\">QLQ<\/jats:styled-content>\u2010C30), were pooled from six bortezomib randomized trials conducted in different disease\u2010stage categories: \u2018New\u2019 (previously untreated; <jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>753), \u2018Early\u2019 (1\u20133 prior therapies; <jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>1569) and \u2018Late\u2019 (\u22654 prior therapies; <jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>239) disease. Mean <jats:styled-content style=\"fixed-case\">EORTC<\/jats:styled-content> global health scores were similar across the three stages. Unexpectedly, emotional, physical and role functioning were higher in the later stages, indicating better perceived health. Symptom scores, including pain, were largely similar or lower in the later <jats:italic>versus<\/jats:italic> earlier stages, signifying a lower symptom burden\/better symptom control with more advanced disease. Notable variation in <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\u2010QoL was observed by age and clinical parameters within and across stages. Multivariate modelling indicated that opioid use and performance status were key factors driving overall <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\u2010QoL across stages. Using an age\u2010restricted analysis, transplant eligibility had little impact on <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\u2010QoL in New disease patients. Thus, changes in <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\u2010QoL over the treatment course of <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> are complex and impacted by baseline factors. A prospective observational international inception cohort study that captures key clinical, HR\u2010QoL and demographic characteristics, along with safety and supportive care information, is needed.<\/jats:p>","DOI":"10.1111\/bjh.14058","type":"journal-article","created":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T01:06:09Z","timestamp":1465175169000},"page":"368-381","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["The influence of baseline characteristics and disease stage on health\u2010related quality of life in multiple myeloma: findings from six randomized controlled trials"],"prefix":"10.1111","volume":"174","author":[{"suffix":"Jr","given":"Don","family":"Robinson","sequence":"first","affiliation":[{"name":"Janssen Global Services Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dixie\u2010Lee","family":"Esseltine","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Regnault","sequence":"additional","affiliation":[{"name":"Mapi Patient\u2010Centred Outcomes Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Meunier","sequence":"additional","affiliation":[{"name":"Mapi Patient\u2010Centred Outcomes Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Liu","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi","family":"van de Velde","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2644-6"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(96)00822-6"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2003.13603.x"},{"key":"e_1_2_9_7_1","first-page":"13","article-title":"The Functional Assessment of Cancer Therapy\u2010Anemia (FACT\u2010An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue","volume":"34","author":"Cella D.","year":"1997","journal-title":"Seminars in Hematology"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01788.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.074534"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.847933"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.099358"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00448-8"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2012.713345"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0902-4441.2003.00195.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01775.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00520-013-1991-4","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health\u2010related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study","volume":"22","author":"Jordan K.","year":"2013","journal-title":"Supportive Care in Cancer"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01404.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-79"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.127860"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12685"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0391"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.5137"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0042"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.06.126"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2015.1021772"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01831.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.5878"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.7618"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23868"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12012"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2264-0"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"e_1_2_9_36_1","first-page":"2487","article-title":"Bortezomib or high\u2010dose dexamethasone for relapsed multiple myeloma. N.Engl","volume":"352","author":"Richardson P.G.","year":"2005","journal-title":"Journal of Medicine"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1611(199907\/08)8:4<344::AID-PON399>3.0.CO;2-T"},{"key":"e_1_2_9_39_1","unstructured":"Scott N.W. Fayers P.M. Aaronson N.K. Bottomley A. deGraeff A. Groenvold M. Gundy C. Koller M. Petersen M.A.&Sprangers M.A.G.;on behalf of the EORTC Quality of Life Group. (2008)EORTC\u2010QLQ\u2010C30 Reference Values (2008). European Organization for Research and Treatment of Cancer Brussels Belgium.http:\/\/groups.eortc.be\/qol\/sites\/default\/files\/img\/newsletter\/reference_values_manual2008.pdf."},{"key":"e_1_2_9_40_1","first-page":"350","article-title":"Health\u2010related quality of life in multiple myeloma survivors treated with high dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation: a retrospective analysis","volume":"55","author":"Slovacek L.","year":"2008","journal-title":"Neoplasma"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08574.x"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.112557"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.185"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-451872"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-010-9592-x"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2011.06.019"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14058","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.14058","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T12:23:49Z","timestamp":1696335829000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,5]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1111\/bjh.14058"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14058","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,5]]},"assertion":[{"value":"2015-11-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-06-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}